Imaging pancreatic beta-cells with PET neuroimaging agent 11C-PHNO
- Study HIC#:2000021287
- Last Updated:03/18/2025
We are conducting a PET imaging study to develop a way to measure the number of insulin secreting cells in the pancreas. This study is intended for people diagnosed with Type 1 and Type 2 Diabetes who are otherwise in good physical health and well controlled on insulin. The study requires 2-3 visits over several weeks - Screening, 1 PET Scan and 1 MRI scan.
- Age18 years - 65 years
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Kayla Cottiers
- Phone Number: 1-203-737-7496
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
As per HIC-approved protocol, 1411014915 (Specific Aim 1), this proposal will continue to explore whether an imaging agent already in use for human neuroimaging, specifically 11C-PHNO, would also be useful for measuring BCM.
Eligibility Criteria
Type 1 Diabetes Inclusion Criteria:
Patients with Type 1 diabetes may be enrolled if they meet all the following criteria: • Are males or females between 18 and 65 years of age; • Have a diagnosis of Type 1 diabetes mellitus defined by ADA criteria or judgment of physician • BMI between 18 and 29 kg/m2 • Able to tolerate PET imaging and MRI • Give informed consent.
Type 2 Diabetes Inclusion Criteria:
Patients with Type 2 diabetes may be enrolled if they meet all the following criteria: • Are males or females between 18 and 65 years of age; • Have a diagnosis of Type 2 diabetes mellitus defined by ADA criteria or judgment of physician • BMI between 18 and 60 kg/m2 • Able to tolerate PET imaging and MRI • Give informed consent.
